Trials@uspto.gov
571-272-7822

Paper 13
Date: May 7, 2024

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

JEISYS MEDICAL INC. and ILOODA CO., LTD.,
Petitioner,

v.

SERENDIA, LLC,
Patent Owner.

IPR2024-00383 (Patent 9,775,774 B2)
IPR2024-00384 (Patent 9,320,536 B2)
IPR2024-00386 (Patent 9,480,836 B2)
IPR2024-00463 (Patent 10,869,812 B2)[1]

Before SHERIDAN K. SNEDDEN, CARL M. DEFRANCO,
TINA E. HULSE, MICHAEL L. WOODS, and SCOTT RAEVSKY,
Administrative Patent Judges.[2]

DEFRANCO, *Administrative Patent Judge*.

DECISION
Granting Termination Only as to Petitioner Ilooda Co., Ltd.
35 U.S.C. § 317; 37 C.F.R. § 42.74

---

[1] This is a consolidated Decision for all four proceedings. Upon entry of this Decision, the caption will be revised to name only Jeisys Medical Inc. as the petitioner.
[2] This is not an expanded panel. Three of the listed judges are assigned to each proceeding.

With our authorization, Petitioner Ilooda Co., Ltd. and Patent Owner Serendia, LLC filed a joint motion to terminate Ilooda as a party in each of the above-identified proceedings pursuant to 35 U.S.C. § 317. *See* IPR2024-00383, Paper 10.[3] Along with the motion, Ilooda and Serendia filed a copy of a settlement agreement, which they request be treated as business confidential information pursuant to 37 C.F.R. § 42.74(c). *Id.* at 1 (citing Ex. 1026).

In the motion, Ilooda and Serendia state that they have settled their dispute regarding the challenged patent in each of the above-identified proceedings and, on that basis, request that the proceedings be terminated as to Ilooda. *Id.* at 2–4. Each proceeding is in a preliminary stage, and we have yet to issue decisions on whether to institute trial. Under these circumstances, we determine it is appropriate to terminate these proceedings only as to Ilooda. *See* 35 U.S.C. § 317; 37 C.F.R. §§ 42.71(a), 42.74.

Ilooda and Serendia also ask that their settlement agreement be treated as business confidential information and be kept separate from the files of the challenged patents. Paper 10, 4–5 (citing Ex. 1026). Pursuant to 37 C.F.R. § 42.74(c), we determine that it is appropriate to treat the settlement agreement as business confidential information and keep it separate from the files of the challenged patents.

---

[3] For convenience, we cite only to papers and exhibits in IPR2024-00383, but substantially identical papers and exhibits are of record in each of the other proceedings.

Accordingly, it is:

ORDERED that the joint motions (IPR2024-00383, Paper 10; IPR2024-00384, Paper 11; IPR2024-00386, Paper 10; IPR2024-00463, Paper 12) are *granted* and these proceedings are terminated only as to Ilooda Co., Ltd.;

FURTHER ORDERED that Jeisys Medical Inc. will continue as Petitioner in these proceedings; and

FURTHER ORDERED that the Settlement Agreement (IPR2024-00383, Exhibit 1026; IPR2024-00384, Exhibit 1027; IPR2024-00386, Exhibit 1038; IPR2024-00463, Exhibit 1022) shall be treated as business confidential information and shall be kept separate from the patent file.

IPR2024-00383 (Patent 9,775,774 B2)
IPR2024-00384 (Patent 9,320,536 B2)
IPR2024-00386 (Patent 9,480,836 B2)
IPR2024-00463 (Patent 10,869,812 B2)

FOR PETITIONER:

Scott Weidenfeller
Peter P. Chen
Anupam Sharma
Wonseon Kiersten Choi
COVINGTON & BURLING LLP
Ilooda-IPR@cov.com
pchen@cov.com
sweidenfeller@cov.com
asharma@cov.com
wchoi@cov.com

Wesley O. Mueller
Leonard Z. Hua
Paul J. Filbin
Brent A. Chatham
LEYDIG, VOIT & MAYER, LTD.
wmueller@leydig.com
lhua@leydig.com
pfilbin@leydig.com
bchatham@leydig.com
Jeisys-IPR@leydig.com

FOR PATENT OWNER:

Charles H. Sanders
Steven W. Peters
LATHAM & WATKINS LLP
charles.sanders@lw.com
steven.peters@lw.com